Resource Logo
Business Wire

Cannabis Science to Present at XIX International AIDS Conference




 

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Dr. Robert Melamede, President and CEO of Cannabis Science (CBIS.OB), will be presenting at the XIX International AIDS Conference (AIDS 2012, www.aids2012.org) taking place in Washington, DC from July 22-27, 2012. Over 30,000 policy makers, researchers, clinicians and advocates from across the globe will be attending the world’s largest and premiere HIV/AIDS conference this year, which is being held in the U.S. for the first time in over two decades.

The biannual International AIDS Conference, first held in 1985 in Atlanta, Georgia, is instrumental in directing HIV/AIDS research and programming and draws leaders from around the world. At this year’s hallmark conference, Dr. Melamede will be presenting at the World AIDS Institute’s Treatment Horizons satellite symposium on Cannabis Science’s new HIV therapeutic research program based on the recent discovery by the Mount Sinai School of Medicine that phytocannabinoids inhibit a key HIV gene called Tat, which controls the virus’s ability to replicate.

Cannabis Science Inc., President & CEO Dr. Robert Melamede Ph. D., states, “Cannabis Science is excited it has the opportunity to present our initial clinical premise during the 19th IAC. Targeting HIV TAT via the antiviral effects of phytocannabioids has the potential to positively impact on millions of persons infected with HIV. We anticipate that CS-TATI-1 will slow the development of the disease as well as the development of resistance treatment."

Tat is an important target for developing new HIV drugs, which are urgently needed. While there are currently 30 antiretroviral drugs on the market, increasing drug resistance to and toxicity from long term use of all existing medications. There is a high demand and need for new treatments to treat HIV in these drug resistance patients; a treatment that will not only control the virus from replicating, but to prevent future drug resistance in current and new patients with HIV.

AIDS 2012 is said to be the largest AIDS conference to date, with over 30,000 participants coming together from 200 different countries. The conference theme, “Turning the Tide Together”, reflects a unique moment in time, emphasizing that the HIV epidemic has reached a defining moment. By acting decisively on recent scientific advances in HIV treatment and biomedical prevention, the momentum for a cure, and the continuing evidence of the ability to scale-up key interventions in the most-needed settings, we now have the potential to end the HIV epidemic. “Turning the Tide Together” evokes both the scale of the task in hand and the power of AIDS 2012 to mobilize governments, NGOs, policy makers, scientists, civil society organizations, journalists and people living with HIV to join forces and build the necessary momentum to turn the tide on HIV and AIDS.

The World AIDS Institute strives to partner with like-minded organizations to help further this important mission. A definitive example is WAI's effort to organize AIDS2012 Reunion this summer surrounding the International AIDS Conference. The Mission of the World AIDS Institute is to document and preserve the global history of AIDS and to empower action today. The World AIDS Institute is dedicated to creating innovative projects designed to preserve that history. A substantial part of our commitment is to ensure the stories of those who led the fight against AIDS and the stories of those who we lost are never forgotten. David Purdy is Founder and Chief Executive Officer of World AIDS Institute. David has dedicated the past 23 years to the education and destigmatization of AIDS to create an acute awareness of this growing problem facing the globe. Successfully battling his own fight with HIV, David has continued to champion for new science and technology that can one day lead to the eradication of this disease.

Cannabis Science is also currently working with CBR International Corp. to develop a pre-IND application to the FDA that focuses on the use of CS-S/BCC-1 cannabinoid-based topical preparations for the treatment of basal and squamous cell carcinomas. CBR International’s Regulatory Strategy and Affairs Group are experienced in developing strategies for companies to proceed through various regulatory pathways to market in the United States and Europe. Their diverse team has the expertise in drugs, biologics and devices to efficiently navigate the regulatory approval process. They have Prepared and submitted over 100 INDs, IND, amendments, IDEs and Annual Reports to FDA. CBR has also Planned and participated in over 20 pre-IND/Pre-IDE meetings with FDA. As well as developed and implemented programs to prepare sponsors for Type A, B, and C meetings with FDA.

Cannabis Science released a press release dated June 5, 2012, titled “Cannabis Science Initiates HIV TAT Anti-Viral Drug Development Program; CS-TATI-1 Lead Hit Discovery Commenced for Pre-Clinical Proof of Concept Development” which, is featured on the AIDS 2012 Reunion Website http://www.aids2012reunion.org/

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contacts

Cannabis Science Inc., Dr. Robert J. Melamede, President & CEO, 1-888-889-0888, info@cannabisscience.com, www.cannabisscience.com

or

Robert Kane, VP Investor Relations, 1-561-234-6929, rkane@cannabisscience.com, info@cannabisscience.com, www.cannabisscience.com



 


Copyright © 2012 -Business Wire, Publisher. All rights reserved to Business Wire.Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. Business Wire.

Information in this article was accurate in June 6, 2012. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.